Interleukin-1 beta inhibition with canakinumab and reducing lung cancer—subset analysis of the canakinumab anti-inflammatory thrombosis outcome study trial (CANTOS)

In the field of cardiovascular disease, the reporting of the Cantos trial was eagerly wait in 2017. It did not disappoint, and we have previously reviewed the cardiovascular implications of IL-1 beta inhibition in patients with cardiovascular risk, defined as a prior myocardial infarction and a hs-CRP >2 mg/L, in this journal (1).